Wealth Enhancement Advisory Services LLC Increases Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Wealth Enhancement Advisory Services LLC grew its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 3.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 5,980 shares of the medical research company’s stock after acquiring an additional 197 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Charles River Laboratories International were worth $1,178,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Versant Capital Management Inc raised its position in Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 150 shares during the period. Wolff Wiese Magana LLC purchased a new stake in shares of Charles River Laboratories International in the 3rd quarter valued at $32,000. Assetmark Inc. raised its holdings in shares of Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after buying an additional 173 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in Charles River Laboratories International during the 3rd quarter worth about $59,000. Finally, Covestor Ltd boosted its holdings in Charles River Laboratories International by 40.9% during the 3rd quarter. Covestor Ltd now owns 327 shares of the medical research company’s stock valued at $65,000 after acquiring an additional 95 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on CRL shares. UBS Group increased their price target on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Bank of America reduced their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. StockNews.com downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Citigroup cut Charles River Laboratories International from a “neutral” rating to a “sell” rating and reduced their price objective for the company from $215.00 to $175.00 in a research note on Tuesday, October 1st. Finally, William Blair reissued an “outperform” rating on shares of Charles River Laboratories International in a research note on Tuesday. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International has an average rating of “Hold” and an average target price of $214.00.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $174.37 on Thursday. The company has a market capitalization of $8.92 billion, a price-to-earnings ratio of 21.82, a price-to-earnings-growth ratio of 4.92 and a beta of 1.38. Charles River Laboratories International, Inc. has a 52-week low of $173.81 and a 52-week high of $275.00. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The stock has a 50 day moving average price of $193.36 and a 200 day moving average price of $199.12.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.43 by $0.16. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company’s revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.72 EPS. Research analysts predict that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.30% of the stock is currently owned by insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).